CATX: perspectivetherapeutics.com Earnings per share for the last twelve months

Graphic logo of perspectivetherapeutics.com (CATX)

Perspective Therapeutics (CATX) currently generates no operating income, relying instead on external investments. The rolling earnings per share metric confirms financial volatility, with the parameter value equal to -1.26. The path forward lies in the development of the targeted alpha therapy platform and new contracts with pharma behemoths. In-house logistics for rare isotopes create a formidable technological barrier, strengthening the company's market position.

CATX Perspective Therapeutics Inc Earnings per share for the last twelve months (06/21/2023 - 11/13/2026)

Perspective Tx (CATX) - metric breakdowns and financial figures

- share price and expert price forecast:
Stock Quotes Perspective Therapeutics Inc|CATX - Fair Value Consensus
- market capitalization information:
Market Value Perspective Therapeutics, Inc.|CATX - Full Business Value
- shareholders' equity book value data:
Net Assets per Single Share Perspective Therapeutics|CATX - Company Book Value|Market Capitalization to Book Value Ratio perspectivetherapeutics.com|CATX - Company Total Assets
- debt and solvency information:
Total Debt to Equity Ratio Perspective Therapeutics|CATX - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Perspective Therapeutics Inc|CATX - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio Perspective Therapeutics, Inc.|CATX - Long-Term Debt|Company Short-Term Debt Perspective Therapeutics|Quick Liquidity perspectivetherapeutics.com
- earnings and multiples data:
CATX - Net Income|Expected Profit Perspective Therapeutics|CATX - Business Payback Period|Future Price to Earnings Perspective Therapeutics Inc|CATX - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Perspective Therapeutics, Inc.|CATX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Perspective Therapeutics|CATX - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months perspectivetherapeutics.com|CATX - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Perspective Therapeutics
Summary company analysis:CATX - perspectivetherapeutics.com
Flagship merchandise of Perspective Tx

For Perspective Therapeutics (CATX), which is developing high-precision radiopharmaceutical cancer therapy, this indicator serves as a measure of how effectively innovation is capitalized into actual revenue. By analyzing the 12-month net income per share trend, an investor sees the result of dividing total net income by the number of securities, allowing for an objective assessment of the return on a unit of shareholder equity.

Main competitors

GERN: Net earnings per share for the last 12 months|Earnings per share for the trailing year NBTX (nanobiotix.com)|Bicycle Therapeutics plc (BCYC) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months CTMX (CytomX Pharma)|Earnings per share for the last twelve months Genelux Corp.|Earnings per share for the last twelve months MOLN|Net earnings per share (EPS TTM) ONCY|Net earnings per share (EPS TTM) lisata.com (LSTA)|Moleculin Biotech - Net earnings per share for the last 12 months|Earnings per share for the last four quarters GRTX (Galera Therapeutics Inc.)|Molecular Templates Corp - Net earnings per share (EPS TTM)